Difference between revisions of "ROS1-rearranged non-small cell lung carcinoma"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
[[Image:Adenocarcinoma_-_ROS1_positive_-_ROS1_--_high_mag.jpg|thumb|right|[[Micrograph]] showing a ROS1-positive [[adenocarcinoma of the lung]]. ROS1 [[immunostain]].]] | |||
'''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK inhibitors]].<ref name=pmid25264305>{{Cite journal | last1 = Shaw | first1 = AT. | last2 = Ou | first2 = SH. | last3 = Bang | first3 = YJ. | last4 = Camidge | first4 = DR. | last5 = Solomon | first5 = BJ. | last6 = Salgia | first6 = R. | last7 = Riely | first7 = GJ. | last8 = Varella-Garcia | first8 = M. | last9 = Shapiro | first9 = GI. | title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 371 | issue = 21 | pages = 1963-71 | month = Nov | year = 2014 | doi = 10.1056/NEJMoa1406766 | PMID = 25264305 }}</ref> | '''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK inhibitors]].<ref name=pmid25264305>{{Cite journal | last1 = Shaw | first1 = AT. | last2 = Ou | first2 = SH. | last3 = Bang | first3 = YJ. | last4 = Camidge | first4 = DR. | last5 = Solomon | first5 = BJ. | last6 = Salgia | first6 = R. | last7 = Riely | first7 = GJ. | last8 = Varella-Garcia | first8 = M. | last9 = Shapiro | first9 = GI. | title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 371 | issue = 21 | pages = 1963-71 | month = Nov | year = 2014 | doi = 10.1056/NEJMoa1406766 | PMID = 25264305 }}</ref> | ||
| Line 36: | Line 37: | ||
Image: Adenocarcinoma - ROS1 positive - ROS1 -- intermed mag.jpg | NSmCC - ROS1 - intermed. mag. | Image: Adenocarcinoma - ROS1 positive - ROS1 -- intermed mag.jpg | NSmCC - ROS1 - intermed. mag. | ||
Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg | NSmCC - ROS1 -high mag. | Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg | NSmCC - ROS1 -high mag. | ||
</gallery> | </gallery> | ||
Revision as of 02:42, 31 December 2019
ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.[1]
General
- ROS1-rearrangements are seen in approximately 1-2% of non-small cell carcinoma.[2]
- Respond to target therapy, e.g. crizotinib.[3]
Microscopic
Features:
- Histology not definitive; however, predictive features are:[4]
Note:
- Most common pattern varies by specimen type:[4]
- Biopsy specimens: solid pattern most common.
- Resection specimens: acinar pattern most common.
Images
NSmCC - low mag.
NSmCC - intermed. mag.
NSmCC - high mag.
NSmCC - very high mag.
NSmCC - TTF-1 - high mag.
NSmCC - napsin A - high mag.
IHC
- ROS1 +ve.
Images
NSmCC - ROS1 - low mag.
NSmCC - ROS1 - intermed. mag.
NSmCC - ROS1 -high mag.
See also
References
- ↑ Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
- ↑ "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. October 2019. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
- ↑ "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. July 2019. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/.
- ↑ 4.0 4.1 "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. 2016. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/.